-
Je něco špatně v tomto záznamu ?
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
A. Shoamanesh, H. Mundl, EE. Smith, J. Masjuan, I. Milanov, T. Hirano, A. Agafina, B. Campbell, V. Caso, JL. Mas, Q. Dong, P. Turcani, H. Christensen, JM. Ferro, R. Veltkamp, R. Mikulik, GM. De Marchis, T. Robinson, R. Lemmens, A. Stepien, S....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie
NLK
ProQuest Central
od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
- MeSH
- antikoagulancia terapeutické užití MeSH
- cévní mozková příhoda * farmakoterapie prevence a kontrola MeSH
- dvojitá slepá metoda MeSH
- faktor XIa MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- ischemická cévní mozková příhoda * MeSH
- ischemie mozku * farmakoterapie prevence a kontrola MeSH
- krvácení chemicky indukované farmakoterapie MeSH
- lidé MeSH
- senioři MeSH
- trombóza * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown. METHODS: In this randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (PACIFIC-Stroke), patients with acute (within 48 h) non-cardioembolic ischaemic stroke were recruited from 196 hospitals in 23 countries. Patients were eligible if they were aged 45 years or older, to be treated with antiplatelet therapy, and able to have a baseline MRI (either before or within 72 h of randomisation). Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs dual), to once daily oral asundexian (BAY 2433334) 10 mg, 20 mg, or 50 mg, or placebo in addition to usual antiplatelet therapy, and were followed up during treatment for 26-52 weeks. Brain MRIs were obtained at study entry and at 26 weeks or as soon as possible after treatment discontinuation. The primary efficacy outcome was the dose-response effect on the composite of incident MRI-detected covert brain infarcts and recurrent symptomatic ischaemic stroke at or before 26 weeks after randomisation. The primary safety outcome was major or clinically relevant non-major bleeding as defined by International Society on Thrombosis and Haemostasis criteria. The efficacy outcome was assessed in all participants assigned to treatment, and the safety outcome was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04304508, and is now complete. FINDINGS: Between June 15, 2020, and July 22, 2021, 1880 patients were screened and 1808 participants were randomly assigned to asundexian 10 mg (n=455), 20 mg (n=450), or 50 mg (n=447), or placebo (n=456). Mean age was 67 years (SD 10) and 615 (34%) participants were women, 1193 (66%) were men, 1505 (83%) were White, and 268 (15%) were Asian. The mean time from index stroke to randomisation was 36 h (SD 10) and median baseline National Institutes of Health Stroke Scale score was 2·0 (IQR 1·0-4·0). 783 (43%) participants received dual antiplatelet treatment for a mean duration of 70·1 days (SD 113·4) after randomisation. At 26 weeks, the primary efficacy outcome was observed in 87 (19%) of 456 participants in the placebo group versus 86 (19%) of 455 in the asundexian 10 mg group (crude incidence ratio 0·99 [90% CI 0·79-1·24]), 99 (22%) of 450 in the asundexian 20 mg group (1·15 [0·93-1·43]), and 90 (20%) of 447 in the asundexian 50 mg group (1·06 [0·85-1·32]; t statistic -0·68; p=0·80). The primary safety outcome was observed in 11 (2%) of 452 participants in the placebo group versus 19 (4%) of 445 in the asundexian 10 mg group, 14 (3%) of 446 in the asundexian 20 mg group, and 19 (4%) of 443 in the asundexian 50 mg group (all asundexian doses pooled vs placebo hazard ratio 1·57 [90% CI 0·91-2·71]). INTERPRETATION: In this phase 2b trial, FXIa inhibition with asundexian did not reduce the composite of covert brain infarction or ischaemic stroke and did not increase the composite of major or clinically relevant non-major bleeding compared with placebo in patients with acute, non-cardioembolic ischaemic stroke. FUNDING: Bayer AG.
1st Department of Neurology Medical Faculty Comenius University Bratislava Slovakia
Bayer US Pharmaceuticals Whippany NJ USA
Clinical Research Department City Hospital 40 Saint Petersburg Russia
College of Life Sciences University of Leicester Leicester UK
Departamento de Medicina Facultad de Medicina Universidad de Alcalá IRYCIS RICORS ICTUS Madrid Spain
Department of Clinical Sciences Lund Lund University Lund Sweden
Department of Medicine McMaster University Population Health Research Institute Hamilton ON Canada
Department of Neurology Amsterdam UMC University of Amsterdam Amsterdam Netherlands
Department of Neurology and Rehabilitation Sciences University of Cincinnati Cincinnati OH USA
Department of Neurology Huashan Hospital Fudan University Shanghai China
Department of Neurology Medical University of Vienna Vienna Austria
Department of Neurology Military Institute of Medicine Warsaw Poland
Department of Neurology Skåne University Hospital Lund Sweden
Department of Neurology University Hospital of Copenhagen Bispebjerg Denmark
Department of Neurology University Hospitals Leuven Leuven Belgium
Department of Neurosciences Experimental Neurology KU Leuven University of Leuven Leuven Belgium
Department of Statistics McMaster University Population Health Research Institute Hamilton ON Canada
Department of Stroke and Cerebrovascular Medicine School of Medicine Kyorin University Tokyo Japan
Division of Clinical Neurosciences University of Turku Turku Finland
Division of Neurology McMaster University Population Health Research Institute Hamilton ON Canada
Medical Faculty Masaryk University Brno Czech Republic
Medical University University Hospital for Neurology and Psychiatry St Naum Sofia Bulgaria
Neurology Department Alfried Krupp Hospital Essen Germany
Neurology Department Hospital Universitario Ramón y Cajal Madrid Spain
Statistics and Data Insights Bayer AG Berlin Germany
Stroke Unit Santa Maria della Misericordia Hospital University of Perugia Perugia Italy
TA Thrombosis and Vascular Medicine Bayer AG Wuppertal Germany
VIB KU Leuven Center for Brain and Disease Research Leuven Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024356
- 003
- CZ-PrNML
- 005
- 20221031100314.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(22)01588-4 $2 doi
- 035 __
- $a (PubMed)36063821
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Shoamanesh, Ashkan $u Division of Neurology, McMaster University, Population Health Research Institute, Hamilton, ON, Canada. Electronic address: ashkan.shoamanesh@phri.ca
- 245 10
- $a Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial / $c A. Shoamanesh, H. Mundl, EE. Smith, J. Masjuan, I. Milanov, T. Hirano, A. Agafina, B. Campbell, V. Caso, JL. Mas, Q. Dong, P. Turcani, H. Christensen, JM. Ferro, R. Veltkamp, R. Mikulik, GM. De Marchis, T. Robinson, R. Lemmens, A. Stepien, S. Greisenegger, R. Roine, L. Csiba, P. Khatri, J. Coutinho, AG. Lindgren, AM. Demchuk, P. Colorado, B. Kirsch, C. Neumann, L. Heenan, L. Xu, SJ. Connolly, RG. Hart, PACIFIC-Stroke Investigators
- 520 9_
- $a BACKGROUND: Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown. METHODS: In this randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (PACIFIC-Stroke), patients with acute (within 48 h) non-cardioembolic ischaemic stroke were recruited from 196 hospitals in 23 countries. Patients were eligible if they were aged 45 years or older, to be treated with antiplatelet therapy, and able to have a baseline MRI (either before or within 72 h of randomisation). Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs dual), to once daily oral asundexian (BAY 2433334) 10 mg, 20 mg, or 50 mg, or placebo in addition to usual antiplatelet therapy, and were followed up during treatment for 26-52 weeks. Brain MRIs were obtained at study entry and at 26 weeks or as soon as possible after treatment discontinuation. The primary efficacy outcome was the dose-response effect on the composite of incident MRI-detected covert brain infarcts and recurrent symptomatic ischaemic stroke at or before 26 weeks after randomisation. The primary safety outcome was major or clinically relevant non-major bleeding as defined by International Society on Thrombosis and Haemostasis criteria. The efficacy outcome was assessed in all participants assigned to treatment, and the safety outcome was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04304508, and is now complete. FINDINGS: Between June 15, 2020, and July 22, 2021, 1880 patients were screened and 1808 participants were randomly assigned to asundexian 10 mg (n=455), 20 mg (n=450), or 50 mg (n=447), or placebo (n=456). Mean age was 67 years (SD 10) and 615 (34%) participants were women, 1193 (66%) were men, 1505 (83%) were White, and 268 (15%) were Asian. The mean time from index stroke to randomisation was 36 h (SD 10) and median baseline National Institutes of Health Stroke Scale score was 2·0 (IQR 1·0-4·0). 783 (43%) participants received dual antiplatelet treatment for a mean duration of 70·1 days (SD 113·4) after randomisation. At 26 weeks, the primary efficacy outcome was observed in 87 (19%) of 456 participants in the placebo group versus 86 (19%) of 455 in the asundexian 10 mg group (crude incidence ratio 0·99 [90% CI 0·79-1·24]), 99 (22%) of 450 in the asundexian 20 mg group (1·15 [0·93-1·43]), and 90 (20%) of 447 in the asundexian 50 mg group (1·06 [0·85-1·32]; t statistic -0·68; p=0·80). The primary safety outcome was observed in 11 (2%) of 452 participants in the placebo group versus 19 (4%) of 445 in the asundexian 10 mg group, 14 (3%) of 446 in the asundexian 20 mg group, and 19 (4%) of 443 in the asundexian 50 mg group (all asundexian doses pooled vs placebo hazard ratio 1·57 [90% CI 0·91-2·71]). INTERPRETATION: In this phase 2b trial, FXIa inhibition with asundexian did not reduce the composite of covert brain infarction or ischaemic stroke and did not increase the composite of major or clinically relevant non-major bleeding compared with placebo in patients with acute, non-cardioembolic ischaemic stroke. FUNDING: Bayer AG.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 12
- $a ischemie mozku $x farmakoterapie $x prevence a kontrola $7 D002545
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a faktor XIa $7 D015945
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a krvácení $x chemicky indukované $x farmakoterapie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a ischemická cévní mozková příhoda $7 D000083242
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 12
- $a cévní mozková příhoda $x farmakoterapie $x prevence a kontrola $7 D020521
- 650 12
- $a trombóza $7 D013927
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Mundl, Hardi $u TA Thrombosis and Vascular Medicine, Bayer AG, Wuppertal, Germany
- 700 1_
- $a Smith, Eric E $u Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Masjuan, Jaime $u Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá, IRYCIS, RICORS-ICTUS, Madrid, Spain
- 700 1_
- $a Milanov, Ivan $u Medical University, University Hospital for Neurology and Psychiatry "St Naum", Sofia, Bulgaria
- 700 1_
- $a Hirano, Teruyuki $u Department of Stroke and Cerebrovascular Medicine, School of Medicine, Kyorin University, Tokyo, Japan
- 700 1_
- $a Agafina, Alina $u Clinical Research Department, City Hospital #40, Saint Petersburg, Russia
- 700 1_
- $a Campbell, Bruce $u Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
- 700 1_
- $a Caso, Valeria $u Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy
- 700 1_
- $a Mas, Jean-Louis $u Department of Neurology, GHU Paris, Hôpital Sainte-Anne, Université Paris-Cité, Inserm U1266, Paris, France
- 700 1_
- $a Dong, Qiang $u Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
- 700 1_
- $a Turcani, Peter $u 1st Department of Neurology, Medical Faculty, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Christensen, Hanne $u Department of Neurology, University Hospital of Copenhagen, Bispebjerg, Denmark
- 700 1_
- $a Ferro, Jose M $u Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 700 1_
- $a Veltkamp, Roland $u Neurology Department, Alfried-Krupp Hospital, Essen, Germany
- 700 1_
- $a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St Anne's University Hospital, Brno, Czech Republic; Medical Faculty, Masaryk University, Brno, Czech Republic
- 700 1_
- $a De Marchis, Gian Marco $u Department of Neurology and Stroke Center, University Hospital of Basel and University of Basel, Basel, Switzerland
- 700 1_
- $a Robinson, Thompson $u College of Life Sciences, University of Leicester, Leicester, UK
- 700 1_
- $a Lemmens, Robin $u Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium; VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Stepien, Adam $u Department of Neurology, Military Institute of Medicine, Warsaw, Poland
- 700 1_
- $a Greisenegger, Stefan $u Department of Neurology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Roine, Risto $u Division of Clinical Neurosciences, University of Turku, Turku, Finland
- 700 1_
- $a Csiba, Laszlo $u DE Clinical Center (DEKK), Health Service Units, Clinics, Department of Neurology, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Khatri, Pooja $u Department of Neurology and Rehabilitation Sciences, University of Cincinnati, Cincinnati, OH, USA
- 700 1_
- $a Coutinho, Jonathan $u Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Lindgren, Arne G $u Department of Clinical Sciences Lund (Neurology), Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Demchuk, Andrew M $u Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Colorado, Pablo $u Bayer US Pharmaceuticals, Whippany, NJ, USA
- 700 1_
- $a Kirsch, Bodo $u Statistics and Data Insights, Bayer AG, Berlin, Germany
- 700 1_
- $a Neumann, Christoph $u Bayer AG, Wuppertal, Germany
- 700 1_
- $a Heenan, Laura $u Department of Statistics, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
- 700 1_
- $a Xu, Lizhen $u Department of Statistics, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
- 700 1_
- $a Connolly, Stuart J $u Department of Medicine, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
- 700 1_
- $a Hart, Robert G $u Division of Neurology, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
- 710 2_
- $a PACIFIC-Stroke Investigators
- 773 0_
- $w MED00010161 $t Lancet $x 1474-547X $g Roč. 400, č. 10357 (2022), s. 997-1007
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36063821 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100311 $b ABA008
- 999 __
- $a ok $b bmc $g 1854209 $s 1175646
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 400 $c 10357 $d 997-1007 $e 20220902 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20221017